- Home
- ASTL vs EDIT Comparison
ASTL vs EDIT Comparison
Compare ASTL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTL | EDIT |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.8M | 432.8M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ASTL | EDIT |
|---|---|---|
| Price | $4.29 | $2.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $5.96 | ★ $6.10 |
| AVG Volume (30 Days) | 539.5K | ★ 3.0M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $57.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $3.16 | $1.66 |
| 52 Week High | $5.90 | $4.33 |
Technical Indicators
Market Signals| Indicator | ASTL | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 40.87 |
| Support Level | $4.05 | $2.46 |
| Resistance Level | $4.49 | $3.18 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 36.45 | 13.64 |
Price Performance
Historical ComparisonAbout ASTL Algoma Steel Group Inc.
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from United States. The company generates the majority of its revenue from the sale of Steel sheets and strips.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.